• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 3. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Tertiary amines

Research Briefing on (2-(bis(ethyl-d5)amino)pyrimidin-5-yl)boronic acid (CAS: 2241877-02-9) and Its Applications in Chemical Biology and Drug Discovery

The deuterated boronic acid derivative, (2-(bis(ethyl-d5)amino)pyrimidin-5-yl)boronic acid (CAS: 2241877-02-9), has recently emerged as a promising compound in chemical biology and medicinal chemistry research. This briefing synthesizes the latest findings regarding its synthesis, physicochemical properties, and potential applications in drug discovery, particularly in the development of proteolysis-targeting chimeras (PROTACs) and kinase inhibitors.

Recent studies have demonstrated that the deuterium substitution in the ethyl groups confers improved metabolic stability to the compound while maintaining its key chemical reactivity. The boronic acid moiety serves as a crucial functional group for Suzuki-Miyaura cross-coupling reactions, making this compound a valuable building block for the synthesis of complex bioactive molecules. A 2023 study published in the Journal of Medicinal Chemistry reported its successful application in the synthesis of BTK-targeting PROTAC molecules with enhanced pharmacokinetic properties.

Structural analyses using X-ray crystallography and NMR spectroscopy have revealed that the pyrimidine core with the bis(ethyl-d5)amino substitution pattern creates a unique electronic environment that influences both the reactivity of the boronic acid group and the overall molecular conformation. This characteristic has been exploited in the design of selective kinase inhibitors, as demonstrated in recent work published in ACS Chemical Biology, where derivatives of this compound showed remarkable selectivity for certain tyrosine kinases.

The compound's potential in PET tracer development has also been explored, with preliminary studies indicating that the deuterated ethyl groups may reduce nonspecific binding while the boronic acid functionality allows for efficient radiolabeling. Research teams at several pharmaceutical companies have included this building block in their fragment libraries for hit identification campaigns, particularly for challenging protein targets.

Ongoing research is investigating the compound's utility in bioorthogonal chemistry applications, where its unique deuteration pattern may provide advantages in metabolic labeling experiments. The most recent patent filings (2023-2024) suggest growing industrial interest in this compound and its derivatives as versatile intermediates for next-generation therapeutics.

In conclusion, (2-(bis(ethyl-d5)amino)pyrimidin-5-yl)boronic acid represents a multifaceted tool in modern drug discovery, combining the advantages of deuterium incorporation with the versatile reactivity of boronic acids. Its applications span from medicinal chemistry to chemical biology, with particular promise in targeted protein degradation strategies and selective kinase inhibition. Further research is expected to uncover additional utilities for this compound as its unique properties continue to be explored.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)